news report
FDA Approves First Oral PCSK9 Drug After 56%–59% LDL Cuts vs. Placebo
Lipfendra adds a once-daily tablet to a cholesterol-lowering drug class previously available only by injection; the pivotal endpoint was LDL change at 24 weeks.
entities
Merck Sharp & Dohme